Aspiration therapy for the treatment of obesity: 4-year results of a multicenter randomized controlled trial
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BACKGROUND The AspireAssist is the first Food and Drug Administration-approved endoluminal device indicated for treatment of class II and III obesity. OBJECTIVES We earlier reported 1-year results of the PATHWAY study. Here, we report 4-year outcomes. SETTING United States-based, 10-center, randomized controlled trial involving 171 participants with the treatment arm receiving Aspiration Therapy (AT) plus Lifestyle Therapy and the control arm receiving Lifestyle Therapy (2:1 randomization). METHODS AT participants were permitted to continue in the study for an additional year up to a maximum of 5 years providing they maintained at least 10% total weight loss (TWL) from baseline at each year end. For AT participants who continued the study, 5 medical monitoring visits were provided at weeks 60, 68, 76, 90, and 104 and thereafter once every 13 weeks up to week 260. Exclusion criteria were a history of eating disorder or evidence of eating disorder on a validated questionnaire. Follow-up weight, quality of life, and co-morbidities were compared with the baseline levels. In addition, rates of serious adverse event, persistent fistula, withdrawal, and A-tube replacement were reported. All analyses were performed using a per-protocol analysis. RESULTS Of the 82 AT participants who completed 1 year, 58 continued to this phase of the trial. Mean baseline body mass index of these 58 patients was 41.6 ± 4.5 kg/m2. At the end of first year (at the beginning of the follow-up study), these 58 patients had a body mass index of 34.1 ± 5.4 kg/m2 and had achieved an 18.3 ± 8.0% TWL. On a per protocol basis, patients experienced 14.2%, 15.3%, 16.6%, and 18.7% TWL at 1, 2, 3, and 4 years, respectively (P < .01 for all). Forty of 58 patients (69%) achieved at least 10% TWL at 4 years or at time of study withdrawal. Improvements in quality of life scores and select cardiometabolic parameters were also maintained through 4 years. There were 2 serious adverse events reported in the second through fourth years, both of which resolved with removal or replacement of the A tube. Two persistent fistulas required surgical repair, representing approximately 2% of all tube removals. There were no clinically significant metabolic or electrolytes disorders observed, nor any evidence for development of any eating disorders. CONCLUSIONS The results of this midterm study have shown that AT is a safe, effective, and durable weight loss alternative for people with class II and III obesity and who are willing to commit to using the therapy and adhere to adjustments in eating behavior.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication
Hudson, J. I., Hiripi, E., Pope, H. G., & Kessler, R. C. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.040 · Cited by 4,973
Kessler, R. C., Berglund, P. A., Chiu, W. T., Deitz, A. C., Hudson, J. I., Shahly, V., Aguilar-Gaxiola, S., Alonso, J., Angermeyer, M. C., Benjet, C., et al. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.11.020 · Cited by 1,338
AGA technical review on obesity
Klein, S., Wadden, T., & Sugerman, H. J. (2002) · Gastroenterology · doi:10.1053/gast.2002.35514 · Cited by 274
Intensive lifestyle intervention for obesity: principles, practices, and results.
Webb, V. L., & Wadden, T. A. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.01.045 · Cited by 167
Nyström, M., Machytka, E., Norén, E., Testoni, P. A., Janssen, I., Turró Homedes, J., Espinos Perez, J. C., & Turro Arau, R. (2018) · Obesity Surgery · doi:10.1007/s11695-017-3096-5 · Cited by 73
Research works printed but not linked: 9
- Xia, 2015, Treatment of obesity: pharmacotherapy trends in the United States from 1999 to 2010, Obesity (Silver Spring), 23, 1721, 10.1002/oby.21136 · DOI · Paper page
- Langeveld, 2015, The long-term effect of energy restricted diets for treating obesity, Obesity, 23, 1529, 10.1002/oby.21146 · DOI · Paper page
- Igel, 2017, Practical use of pharmacotherapy for obesity, Gastroenterology, 152, 1765, 10.1053/j.gastro.2016.12.049 · DOI
- Buchwald, 2013, Metabolic/Bariatric surgery worldwide 2011, Obes Surg, 23, 427, 10.1007/s11695-012-0864-0 · DOI · Paper page
- Sullivan, 2013, Aspiration therapy leads to weight loss in obese subjects: a pilot study, Gastroenterology, 145, 1245, 10.1053/j.gastro.2013.08.056 · DOI · Paper page
- Thompson, 2017, Percutaneous gastrostomy tube device for the treatment of class II and class III obesity: results of a randomized controlled trial, Am J Gastroenterol, 112, 447, 10.1038/ajg.2016.500 · DOI · Paper page
- Cossrow, 2016, Estimating the prevalence of binge eating disorder in a community sample from the United States: comparing DSM-IV-TR and DM-5 Criteria, J Clin Psychiatry, 77, e968, 10.4088/JCP.15m10059 · DOI · Paper page
- Udo, 2018, Prevalence and correlates of DSM-5-defined eating disorders in a nationally representative sample of U.S. adults, Biol Psychiatry, 84, 345, 10.1016/j.biopsych.2018.03.014 · DOI · Paper page
- Palavras, 2011, A review of Latin American studies on binge eating disorder, Revista brasileira de psiquiatria (Sao Paulo, Brazil: 1999), 33, S81, 10.1590/S1516-44462011000500007 · DOI
Cited by
Di Lorenzo, N., Antoniou, S. A., Batterham, R. L., Busetto, L., Godoroja, D., Iossa, A., Carrano, F. M., Agresta, F., Alarçon, I., Azran, C., et al. (2020) · Surgical Endoscopy · doi:10.1007/s00464-020-07555-y · Cited by 465
Effect of Aspiration Therapy on Obesity-Related Comorbidities: Systematic Review and Meta-Analysis
Jirapinyo, P., de Moura, D. T. H., Horton, L. C., & Thompson, C. C. (2020) · Clinical Endoscopy · doi:10.5946/ce.2019.181 · Cited by 32
Self-citationEndoscopic bariatrics: current therapies and future directions
Reja, D., Zhang, C., & Sarkar, A. (2022) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2020.03.09 · Cited by 24
“7% at 1, 2, 3, and 4 years, respectively (40).”
Updates in endoscopic bariatric and metabolic therapies.
Qureshi, H., Saeed, N., & Jovani, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12031126 · Cited by 21
“The main reasons for discontinuation were fatigue with the therapy or achievement of desired weight loss [48,49].”
BackgroundRen, M., Zhou, X., Lv, L., & Ji, F. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00448 · Cited by 12
Metadata
- Authors
- Thompson, C. C., Abu Dayyeh, B. K., Kushnir, V., Kushner, R. F., Jirapinyo, P., Schorr, A. B., Aronne, L. J., Amaro, A., Jaffe, D. L., Schulman, A. R., Early, D., Stein, A. C., Sharaiha, R., Edmundowicz, S. A., Bohning, J. M., Jensen, M. D., Shukla, A. P., Apovian, C., Kim, D. W., Tran, D., Zarrinpar, A., Ryan, M. B., Young, M., Lowe, A., Haas, M., Goldsmith, H., McCrea, J., & Sullivan, S.
- Venue
- Surgery for Obesity and Related Diseases
- Publisher
- Elsevier BV
- Published
- 2019-08
- Volume
- 15
- Issue
- 8
- Pages
- 1348-1354
- ISSN
- 1550-7289 (ISSN-L)
- OpenAlex
- W2943511454
- Cited by
- 56
- References
- 5
- FWCI
- 7.99
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aspiration therapy for the treatment of obesity: 4-year results of a multicenter randomized controlled trial. https://app.cochat.ai/papers/10.1016/j.soard.2019.04.026
- The paper
- Thompson, C. C., Abu Dayyeh, B. K., Kushnir, V., Kushner, R. F., Jirapinyo, P., Schorr, A. B., Aronne, L. J., Amaro, A., Jaffe, D. L., Schulman, A. R., Early, D., Stein, A. C., Sharaiha, R., Edmundowicz, S. A., Bohning, J. M., Jensen, M. D., Shukla, A. P., Apovian, C., Kim, D. W., . . . Sullivan, S. (2019). Aspiration therapy for the treatment of obesity: 4-year results of a multicenter randomized controlled trial. Surgery for Obesity and Related Diseases. https://doi.org/10.1016/j.soard.2019.04.026
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.